...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Molecular and Cellular Pharmacology >Pembrolizumab as First-line Therapy for PD-L1-expressing Lung Cancer
【24h】

Pembrolizumab as First-line Therapy for PD-L1-expressing Lung Cancer

机译：Pembrolizumab作为表达PD-L1的肺癌的一线治疗

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Pembrolizumab is an immune checkpoint inhibitor antibody. It is a humanized monoclonal antibody directed against cytotoxic T cell immune checkpoint receptor named programmed death 1 (PD-1) (1, 2). PD1 is believed to transduce inhibitory signals when bound to its ligand PD-L1 or PD-L2 (1, 2). Pembrolizumab when bound to PD1 is believed to block PD1 interactions with PD-L1/PD-L2 and consequently enhances cytotoxic T cell effects on tumor cells (1, 2). In a recent article, Reck et al., (3) reported the results from a phase 3 trial that compared pembrolizumab with platinum-based chemotherapy in PD-L1-positive non-small-cell lung cancer (NSCLC). The previously untreated advanced NSCLC patients included in the study had 50% or higher of their tumor cells expressed PD-L1. The patients also did not have sensitizing EGFR mutation or ALK gene translocation. Progression-free survival was the primary endpoint and the secondary endpoints included overall survival, objective response rate and safety. The results indicated a longer progression-free survival in the pembrolizumab arm compared to that in the chemotherapy arm. In relation to secondary endpoints, promising results were also obtained in the pembrolizumab arm. Thus, pembrolizumab exhibited a promising potential as a first line option for a select group of NSCLC patients that had PD-L1 expression on 50% or higher of their tumor cells.
机译：派姆单抗是一种免疫检查点抑制剂抗体。它是一种针对细胞毒性T细胞免疫检查点受体的人源化单克隆抗体，称为程序性死亡1（PD-1）（1、2）。当与PD1的配体PD-L1或PD-L2结合时，PD1被认为可转导抑制性信号（1、2）。认为Pembrolizumab与PD1结合时会阻断PD1与PD-L1 / PD-L2的相互作用，因此增强了对肿瘤细胞的细胞毒性T细胞效应（1、2）。 Reck等人（3）在最近的一篇文章中报告了一项3期试验的结果，该试验比较了Pembrolizumab与铂类化疗治疗PD-L1阳性非小细胞肺癌（NSCLC）。纳入研究的先前未接受治疗的晚期NSCLC患者的肿瘤细胞中有50％或更高的细胞表达了PD-L1。患者也没有致敏的EGFR突变或ALK基因易位。无进展生存期是主要终点，次要终点包括总体生存期，客观缓解率和安全性。结果表明，与化疗组相比，pembrolizumab组的无进展生存期更长。关于次要终点，在pembrolizumab组中也获得了可喜的结果。因此，对于选择的在其肿瘤细胞的50％或更高表达PD-L1的NSCLC患者的一线选择，pembrolizumab具有潜在的前途潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号